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Introduction
Substantial experimental evidence now exists to show that G protein-coupled receptors (GPCRs) can productively couple to G proteins in the absence of agonist to produce a measurable downstream response Kenakin, 2004) , a phenomenon which is termed constitutive activity. To accommodate these empirical observations, the "extended ternary complex" model (Samama, et al., 1993 ) and the more thermodynamically complete "cubic ternary complex model" (Weiss, et al., 1996a) were developed. Central to these models is the concept that receptors exist in an equilibrium between inactive (R) and active (R*) receptor conformations. The enhanced ability to detect constitutive activity led to the discovery of a unique subclass of ligands, which exert their actions by actively reducing basal receptor activity. This novel pharmacological property, termed "inverse agonism," has been modeled by assuming that inverse agonists preferentially bind and stabilize the inactive R state of the receptor (Leff, 1995) .
According to the simplest interpretation of the two-state receptor model, the constitutively active R* conformation ought to be identical with the agonist induced AR*, because there is only one single active conformational state. However, there is no a priori reason that this has to be the case. By analogy to ionic channels and enzymes, it is likely that a receptor may possess multiple, distinct active conformations, as supported by increasing evidence (Kenakin, 2003) .
Here, we report novel findings on the human muscarinic acetylcholine receptor subtype 3 (hM3-R), which belongs to the seven transmembrane-containing superfamily This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on November 5, 2017 jpet.aspetjournals.org Downloaded from of G protein-coupled receptors (GPCRs) and stimulates intracellular inositol trisphosphate production by a G q/11 -mediated mechanism (Wess, 1993) . In airway diseases such as chronic obstructive pulmonary disease (COPD) and asthma, the hM3-R, which is highly expressed on airway smooth muscle cells, is an important pharmacological target: its activation in response to acetylcholine (ACh), which is released from parasympathetic nerve endings, causes bronchoconstricton. Indeed, muscarinic antagonists such as ipratropium or tiotropium are effective bronchodilators which have a particular value in the treatment of COPD, because they block the effects of an increased vagal cholinergic tone (Barnes, 2004) .
In the present study, we examined the inhibitory properties of several muscarinic antagonists in a system where both constitutive activity and agonist-induced responses at the human M 3 receptor could be observed. Our results support the idea that, despite inducing the same intracellular signalling cascade (here G q coupling), the constitutively active M3-R* and the agonist-stabilized M3-AR* may represent distinct conformational states of the receptor, which are differently recognized by some antagonists. These findings support a model of G protein-coupled receptor activation in which the assumption of two states (active and inactive) is expanded to include two or more active conformations. Also, we found evidence that the different anticholinergics have distinct pharmacological behaviours. Therefore, the assumption that inverse agonists operate by stabilizing a common inactive conformation of the receptor may be too simplistic.
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Ipratropium bromide, tiotropium bromide, aclidinium bromide and glycopyrrolate bromide were synthesized in the chemical laboratories of Boehringer Ingelheim, Biberach an der Riss, Germany. The tritiation of tiotropium was carried out by RC Tritec AG (Teufen, Switzerland).
[3H]-tiotropium was purified by HPLC on a XBridge (Waters GmbH, Eschborn, Germany) C-8 column resulting in a radiochemical purity ≥ 98%, and a specific activity of 65 Ci/mmol. All cell culture reagents were purchased from GIBCO (Invitrogen, Carlsbad, CA).
Cell culture techniques
Chinese hamster ovary (CHO) cells stably transfected with the cDNA encoding the human M3 muscarinic acetylcholine receptor (hM3-R) were previously described supplemented with 10% fetal calf serum in the presence of the selection agent G418 (400 µg/ml). Cells were maintained at 37°C in humidified air containing 5% CO 2 .
Transient transfection for reportergene
One day in advance, two million CHO-hM3 cells were plated in a 6 well dish in Ham´s F12 medium containing 10% FCS. The following day, cells, typically 50 to 60 % confluent, were transiently transfected with the AP-1 luciferase reportergene (PathDetect AP-1 Cis-Reporter Plasmid, Stratagene, La Jolla, CA) using the transfection reagent FuGENE 6 (Roche Diagnostics, Mannheim, Germany) optimized at 2 µg of DNA / 6 µl of FuGENE 6 per well, according to the manufacturer's protocol.
Detection of functional antagonism with the AP-1 luciferase assay
30 hours after transfection of the AP-1 luciferase cDNA, CHO-hM3 cells were resuspended in DMEM-F12 medium without phenol red containing 2% FCS and transferred to 384 white well plates (Perkin Elmer, Waltham, MA), where they were stimulated with a range of carbachol concentrations (from 10 -9 to 10 -2 M), in the presence or absence of at least 7 different concentrations of antagonists. 
Chemical stability studies
To analyze their degradation kinetics, compounds were dissolved in 0.1 mol/l KH 2 PO 4 buffer pH 7.4 at a concentration of ca. 0.35 mg/ml. The solutions were filled in 2 ml HPLC glass vials and were placed in a thermostated autosampler which was held at 37 °C. HPLC-diagrams were collected every 2 hours for a total of 20 hours. The RP-HPLC (Agilent HP 1100 with diode array detector, equipped with Prontosil C18 ace-EPS column, 125 mm length, 4.6 mm inner diameter) setup consisted in a gradient between eluent A (10 mmol/l ammonium acetate sol. pH 7.0) and eluent B (acetonitrile) with a flow rate of 1ml/min and quantitative detection at 240 nm. The obtained diagrams were analysed using a first order degradation approach.
Data analysis
All experiments were analysed by either linear or non-regression analysis with the equations mentioned under the different assay methodology using Prism version 5.02
(GraphPad Software, San Diego, CA). Individual estimates (either pA 2 , pIC 50 or pEC 50 values) were obtained from each experiment and then averaged to provide mean data (± S.E.M). The statistical significance of differences between data were determined using 
Results
Selection of an appropriate reporter gene for monitoring hM 3 receptor activation
The hM3-R couples to G q proteins, resulting in activation of phospholipase C (PLC) (Wess, 1993) . Previously, functional antagonism of a series of muscarinic antagonists was characterized in our laboratory by measuring changes in the intracellular concentrations of inositol phosphates . Although having several advantages, such as the ease of performance, sensitivity and reproducibility, this assay has a major limitation, namely the fact that its stimulation time cannot be prolonged for more than 1-2 hours. This aspect is of particular importance when considering ligands with slower kinetics of dissociation from the hM3 receptor, the so-called long acting muscarinic antagonists (LAMAs), e.g. tiotropium (dissociaton t 1/2 27h), aclidinium (t 1/2 11h) and glycopyrrolate (t 1/2 6h). LAMAs are unable to reach pseudo-equilibrium within this time frame, resulting in deviation of the Schild plot from unity ).
To overcome this problem, we intended to set up a reporter-gene assay with longer incubation times, using the same CHO-hM3 cell line previously used for the InsP assay, to allow for direct comparison of results. Given the G q coupling of the hM3 receptor, efforts concentrated on the firefly-luciferase reporter construct under the control of the AP-1 promoter, which typically depends on PKC activation (Angel and Karin, 1991) . As Under these conditions, the effects of the different agonists carbachol, muscarine, oxotremorine and pilocarpine were tested (figure 2). Each agonist stimulated a concentration-dependent increase in luciferase, with the following pEC 50 values:
carbachol, 6.5 ± 0.1; muscarine, 6.7 ± 0.1; oxotremorine, 6.9 ± 0.1 and pilocarpine, 6.0 ± 0.1; n ≥ 3). The reporter assay also allowed for a sensitive assessment of agonist intrinsic activity: compared to carbachol and muscarine, which behaved as full agonists, oxotremorine and pilocarpine exhibited intrinsic activities of 81 ± 3% and 52 ± 2%, respectively (n = 3).
Characterization of antagonistic behaviour at the hM3-R with the AP-1 driven reporter gene
This article has not been copyedited and formatted. The final version may differ from this version. concentrations. This represents an advantage to previous results obtained with the inositol phosphate (InsP) assay , where fitting the dose ratios over a large range of LAMAs concentrations resulted in linear regressions with a slope significantly higher than 1 (slopes were 1.29 ± 0.05; 1.27 ± 0.07 and 1.27 ± 0.05 for tiotropium, aclidinium, and glycopyrrolate, respectively; see Compared to the agonist-induced response, approximately 30% of the total hM3 response corresponds to basal, agonist independent, signalling ( figure 5A ). All the antagonists tested behaved as full inverse agonists concentration-dependently decreasing the M3-R basal activity to the same minimum ( figure 5B and C) .
The half-maximal inhibitory concentrations of the different anticholinergics necessary to block the hM3-R constitutive signalling are reported in table 1. When comparing their potencies in inhibiting the agonist-induced response (pA 2 values against carbachol) and the constitutive signalling of the hM3 receptor (pIC 50 ) in the same luciferase assay, the tested anticholinergics revealed different behaviours: whereas most (i.e. atropine, pirenzepine, ipratropium, glycopyrrolate, DAMP) were equi-potent as antagonists and inverse agonists, others (i.e. NMS and tiotropium) showed a significantly higher propensity to inhibit the agonist response than the constitutive activity of the receptor (3.16-and 8.3-fold difference for NMS and tiotropium, respectively). Aclidinium was the only compound to show the opposite trend, i.e. higher potency as inverse agonist;
however, due to the compound inherent instability, large variability was present in the different assays (see e.g. figure 5B ) and therefore a large error was associated with the measurements, hampering the reaching of statistical significance.
Taken together, these results suggest that the constitutively active M3-R* and the agonist stabilized M3-AR*, although activating the same pathway, represent distinct conformational states of the receptor, which are differently recognized by some but not all antagonists.
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Effects of Chronic Exposure to Inverse Agonists on Receptor Expression Levels.
Next we assessed whether co-incubation with ligands shown to suppress hM3-R constitutive activity could affect receptor expression levels. In these experiments, CHO cells were incubated for 30 hours with the different antimuscarinics before measuring M3-R expression at the cell surface with a binding assay using [
3 H]-tiotropium as marker.
Given the slow dissociation kinetics of some of the muscarinic antagonists, the so called LAMAs , care was taken to develop a washing procedure which would fully remove these compounds bound to the M3-R and allow [ 
Discussion
Detection of different hM3-R active conformations
Here we describe the set-up of a read-out system, namely an AP-1-driven reporter-gene, which allows the detection of both agonist-induced as well as constitutive activity for the hM3 receptor (hM3-R). Interestingly, pharmacological characterization of a series of anticholinergics indicates disparate pharmacological behaviour upon receptor interaction.
Although all the antagonists studied here can be classified as full inverse agonists based on their ability to decrease agonist-independent activation of the AP-1 transcription factor, we found interesting differences in the pharmacology of these compounds when comparing their respective potencies as neutral antagonists (i.e. their pA 2 values against carbachol) and as inverse agonists (table 1) , respectively. Our interpretation of these data implies the presence of different active hM3-R conformations, either stabilized by agonists such as carbachol and muscarine (M3-AR*) or by the agonist-free active conformation itself (M3-R*). Importantly, antagonists tested in these assays are orthosteric to each other and to the agonist carbachol , ruling out the probe-dependency seen with allosteric antagonists as a potential explanation for these pharmacological discrepancies.
The present finding that M3-R* and M3-AR* represent different conformations, which are differently recognized by some antagonists, is in general agreement with the emerging concept of multiple active states for a given receptor. Observations supporting this novel concept have been reported for many GPCRs (Kenakin, 2003 (Kenakin, 2003) .
Instead, our current results, i.e. the pharmacological differences observed with some antagonists in blocking agonist-induced and constitutive activation of the AP-1 transcription factor, suggest that for the hM3-R multiple active conformations exist for the regulation of the same signalling pathway, namely G q coupling. These findings are in agreement with biophysical studies obtained using ß 2 -adrenoceptors fluorescently labelled at Cys265, a region that is sensitive to receptor conformational changes (Ghanouni, et al., 2001) . Fluorescence lifetime spectroscopy showed that different ß-agonists produced different arrays of receptor conformations, consistent with ligandselective active states. Instead of a single receptor active state for G-protein activation,
there is an ensemble of microconformations (Kenakin, 2002) that are all capable of producing the same pharmacological effect (in this case, G q -protein activation) but having different overall tertiary conformations.
Detection of constitutive activity also allowed for pharmacological differentiation among the tested anticholinergics: although for most compounds pA 2 values and inverse agonist potencies were in close agreement, NMS and tiotropium showed a significantly lower potency as inverse agonists (without affecting their negative intrinsic activity).
These data suggest that the different anticholinergics stabilize different conformations, and possibly that they achieve their inverse agonistic effect via distinct mechanisms of action. Classically, inverse agonists are envisioned as ligands that stabilize the inactive R conformation (Leff, 1995) . One alternative mode of inverse agonist action has been proposed (Strange, 2002 inactive state that still retains the ability to bind and sequester G proteins but is unable to activate them. A species of receptor that is inactive but still binds G protein is one of the key features of the cubic ternary complex model (Weiss, et al., 1996) which distinguishes it from the extended ternary complex model.
Differences in antagonists' mediated hM3-R upregulation
It is generally assumed that inverse agonists might cause receptor upregulation: their inhibition of the spontaneous formation of receptor active states and consequent phosphorylation and internalization, coupled with normal receptor synthesis and expression, would lead to an increased surface density of receptor (Milligan and Bond, 1997) . However, most studies analyzing the effects of inverse agonists on receptor upregulation were performed with constitutively active (CAM) receptor mutants (Dowling, et al., 2006; Zeng, et al., 2003) . Unfortunately, interpreting results obtained with CAM receptors is not always straight-forward: the creation of a CAM can diminish stabilizing constraints within the receptor, leading to an inherently unstable receptor that is more susceptible to destabilization and/or proteolytic degradation (Milligan and Bond, 1997 ).
Consequently, the expression level of the mutant is increased by any ligand, either agonist or antagonist, regardless of its efficacy, as shown e.g. with a constitutively active chimeric M3-R (Zeng, et al., 2003) . Here instead, we tested the ability of the different anticholinergics to upregulate the WT hM3-R, ruling out potential artefacts. Again, (Azzi, et al., 2003) .
Physiological relevance of hM3-R constitutive activity
Presently, the physiological importance of constitutive activity for GPCRs is unclear.
Accumulating evidence for its potential role comes from studies showing constitutive signalling in cells endogenously expressing the receptor of interest (de Ligt, et al., 2000) .
However, evidence of GPCR constitutive activity in vivo is still scarce, with few excellent studies detailing inverse agonism at GPCRs expressed in vivo in native systems (e.g. (De, et al., 2004; Morisset, et al., 2000) ). Additionally, somatic receptor mutations leading to constitutively active receptors are a causal factor in certain diseases, e.g. retinitis pigmentosa, congenital night blindness and familial hyperthyroidism (de Ligt, et al., 2000) . The extent to which GPCRs are constitutively active is dependent on the level of receptor and G protein expression levels: generally, in efficiently coupled tissues with large receptor reserves, this may be an important factor in the pharmacological control of tissue function (Kenakin, 2004) .
The physiological role of hM3-R constitutive signaling is currently unknown. There is however evidence that an increased cholinergic tone may be an important feature of chronic pulmonary diseases such as COPD (Barnes, 2004b; Barnes, 2004a) . This increased cholinergic tone might, at least in part, result from an increase in the constitutive signalling of hM3 receptors, as suggested by recent studies indicating an upregulation of M3-R in COPD patients, compared to healthy individuals (Profita, et al., 2005; Profita, et al., 2009) . Additionally, increasing the expression levels of effector proteins also influences the basal signaling of GPCRs: for example, artificial overexpression of Gα q proteins greatly enhances the constitutive activity of hM3-R in a cellular model (Burstein, et al., 1995) . To this end, it has been shown that proinflammatory stimuli known to play a role in the pathogenesis of COPD, such as TNF-α and cigarette smoke, increase the expression of Gα q and Rho proteins (Chiba, et al., 2005; Hotta, et al., 1999) , which are known signalling partners for the hM3-R. If indeed constitutive activity were operative in this pathology, inverse agonists would be uniquely valuable in the retardation of disease progression. An important appendix to the use of inverse agonists in the clinical practice relates to their potential to induce receptor upregulation and tolerance upon chronic treatment. Indeed, studies have indicated the upregulation of muscarinic receptors as a consequence of chronic atropine administration in animals (Chevalier, et al., 1991; Wall, et al., 1992) ; in particular, chronic exposure to atropine resulted in an upregulation of M3-R that was associated with enhanced airway smooth muscle contraction in rabbits (Witt-Enderby, et al., 1995) , Negative efficacy is a molecular property of anticholinergics which might be desirable in clinical use for COPD, but attention should be paid to their potential for receptor upregulation, leading to tolerance and possibly a rebound effect upon antagonist withdrawal. Importantly, our results indicate that it is possible to dissociate inverse agonistic properties from potential to induce upregulation, as it has been seen for example with tiotropium. In agreement with these results, recent data from the UPLIFT (Understanding Potential Long-term Impacts on Function with Tiotropium) study involving almost 6000 COPD patients indicated no loss of tiotropium bronchodilatory effects throughout the trial, which lasted 4 years, ruling out tolerance to this drug in the clinical setting (Tashkin, et al., 2008) . Schild regression of tiotropium is shown for the data obtained with 18 hours incubation.
A slope of 1.07 of the linear regression over a large range of tiotropium concentrations ensures that equilibrium conditions were reached within this time frame. gene (filled circles, slopes: 1.00 ± 0.03 and 1.05 ± 0.02 for atropine and tiotropium, respectively), compared to the data previously obtained with the inositol phosphate assay (empty circles) are shown . Data are the mean of at least three independent experiments (± S.E.M.). 
